Patents by Inventor John Messenheimer

John Messenheimer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20230414533
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 30, 2023
    Publication date: December 28, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of Fragile X Syndrome with cannabidiol
    Patent number: 11779549
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: October 10, 2023
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20230000790
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 24, 2022
    Publication date: January 5, 2023
    Applicants: ZYNERBA PHARMACEUTICALS, INC., ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of Fragile X Syndrome with cannabidiol
    Patent number: 11458110
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: October 4, 2022
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF BEHAVIORAL IMPAIRMENT IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
    Publication number: 20220218625
    Abstract: The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.
    Type: Application
    Filed: March 17, 2022
    Publication date: July 14, 2022
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Donna Gutterman, John Messenheimer
  • TREATMENT OF SYNGAP1 ENCEPHALOPATHY
    Publication number: 20210077421
    Abstract: The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.
    Type: Application
    Filed: September 16, 2020
    Publication date: March 18, 2021
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, John Messenheimer, Donna Gutterman
  • SYNTHETIC TRANSDERMAL CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS
    Publication number: 20210030665
    Abstract: The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.
    Type: Application
    Filed: August 18, 2020
    Publication date: February 4, 2021
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Donna Gutterman, Terri Sebree, Ted Smith, John Messenheimer
  • TREATMENT OF FRAGILE X SYDROME WITH CANNABIDIOL
    Publication number: 20200360299
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 6, 2020
    Publication date: November 19, 2020
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of fragile x syndrome with cannabidiol
    Patent number: 10758497
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: September 1, 2020
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • METHODS OF TREATMENT OF OSTEOARTHRITIS WITH TRANSDERMAL CANNABIDIOL GEL
    Publication number: 20200170963
    Abstract: A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition. A method is disclosed for treating one or more symptoms of osteoarthritis in a patient. The method includes transdermally administering an effective amount of cannabidiol (CBD) to the patient wherein one or more symptoms of osteoarthritis are treated in the patient.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 4, 2020
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Nancy Tich, John Messenheimer, Donna Gutterman, Daniel Clauw
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20200030255
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: October 7, 2019
    Publication date: January 30, 2020
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of fragile X syndrome with cannabidiol
    Patent number: 10471022
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: November 12, 2019
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20190167605
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: January 16, 2019
    Publication date: June 6, 2019
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • SYNTHENTIC TRANSDERMAL CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS
    Publication number: 20190083388
    Abstract: The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.
    Type: Application
    Filed: September 18, 2018
    Publication date: March 21, 2019
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Donna Gutterman, Terri Sebree, Theodore Smith, John Messenheimer
  • Treatment of fragile X syndrome with cannabidiol
    Patent number: 10213390
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: February 26, 2019
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree